Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.17 (
lysozyme
)
21,489
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glycol chitosan (GC) is a hydrophilic chitosan derivative, known for its aqueous solubility. Previously, we have demonstrated the feasibility of preparing injectable, enzymatically crosslinked hydrogels from
HPP
[3-(4-Hydroxyphenyl)-propionic acid (98%)]-modified GC. However,
HPP
-GC gels showed very slow degradation, which presents challenges as an
in vivo
protein delivery vehicle. This study reports the potential of acetylated
HPP
-GC hydrogels as a biodegradable hydrogel platform for sustained protein delivery. Enzymatic crosslinking was used to prepare injectable, biodegradable hydrogels from
HPP
-GC with various degrees of acetylation (DA). The acetylated polymers were characterized using Fourier transform infrared and nuclear magnetic resonance spectroscopy. Rheological methods were used to characterize the mechanical behavior of the hydrogels.
In vitro
degradation and protein release were performed in the presence and absence of
lysozyme
.
In vivo
degradation was studied using a mouse subcutaneous implantation model. Finally, two hydrogel formulations with distinct
in vitro
/
in vivo
degradation and
in vitro
protein release were evaluated in 477-SKH1-Elite mice using live animal imaging to understand
in vivo
protein release profiles. The
lysozyme
-mediated degradation of the gels was demonstrated
in vitro
and the degradation rate was found to be dependent on the DA of the polymers.
In vivo
degradation study further confirmed that gels formed from polymers with higher DA degraded faster.
In vitro
protein release demonstrated the feasibility to achieve
lysozyme
-mediated protein release from the gels and that the rate of protein release can be modulated by varying the DA.
In vivo
protein release study further confirmed the feasibility to achieve differential protein release by varying the DA. The feasibility to develop degradable enzymatically crosslinked GC hydrogels is demonstrated. Gels with a wide spectrum of degradation time ranging from less than a week and more than 6 weeks can be developed using this approach. The study also showed the feasibility to fine tune
in vivo
protein release by modulating
HPP
-GC acetylation. The hydrogel platform therefore holds significant promise as a protein delivery vehicle for various biomedical and regenerative engineering applications. Impact statement The study describes the feasibility to develop a novel enzyme sensitive biodegradable and injectable hydrogel, where in the
in vivo
degradation rate and protein release profile can be modulated over a wide range. The described hydrogel platform has the potential to develop into a clinically relevant injectable and tunable protein delivery vehicle for a wide range of biomedical applications.
...
PMID:Degradation-Dependent Protein Release from Enzyme Sensitive Injectable Glycol Chitosan Hydrogel. 3294 Jan 46